The Food and Drug Administration issued new breast implant guidance on Wednesday, recommending that manufacturers include serious warning labels about the potential complications and risks. The administration recommended that breast implants carry a 'boxed warning,' its strongest form of warning
The Food and Drug Administration issued new breast implant guidance on Wednesday, recommending that manufacturers include serious warning labels about the potential complications and risks.
"We believe women should have thoughtful and balanced discussions with their health care providers about both the benefits and risks of breast implants based on clear and current information," the statement said."We have heard from many women that they are not fully informed of the risks when considering breast implants. They’ve stated that they need more information to facilitate meaningful conversations with their doctors and to make appropriate decisions for themselves.
In July, pharmaceutical company Allergan recalled several models of its textured breast implants that were directly linked to BIA-ALCL. The company announced the decision following a recommendation from the FDA. It said the risk of BIA-ALCL in patients with Allergan BIOCELL textured implants is around six times higher than the risk of it in patients with textured implants from other manufacturers in the U.S.
The administration also recommends that manufacturers include a patient decision checklist at the end of a patient informational booklet or brochure.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FDA Approves New Drug for Most Common Form of Cystic FibrosisActing FDA Commissioner Dr. Ned Sharpless said the approval was an outgrowth of efforts to speed development of new therapies for complex diseases.
Lire la suite »
Biogen, in Reversal, Will Seek FDA OK for Alzheimer’s Drug After Further AnalysisBiogen said it plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease, after pulling the plug on phase 3 studies of the drug earlier this year.
Lire la suite »
In dramatic turn, Biogen seeks FDA approval for experimental Alzheimer's drugBiogen Inc. announces it will seek approval for an experimental Alzheimer’s treatment from the FDA. The announcement comes as a shock because Biogen had recently killed studies of the same drug on the grounds that it was unlikely to work.
Lire la suite »
Biogen CEO 'reasonably confident' once-doomed Alzheimer's drug will be granted FDA approval'This was a thorough engagement, and as CEO I'm reasonably confident this will lead to market approval one day,' Biogen CEO Michel Vounatsos says.
Lire la suite »
GSK gets FDA nod for wider use of ovarian cancer drug ZejulaGlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Z...
Lire la suite »
FDA approves 'miracle' treatment for cystic fibrosis'It's not a cure, but it's the closest thing we have,' a doctor said of a new cystic fibrosis treatment.
Lire la suite »